3.47
+0.09(+2.66%)
Currency In USD
Address
100 Overlook Center
Princeton, NJ 08540
United States of America
Phone
609-375-2227
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
October 31, 2006
| Name | Title | Pay | Year Born |
| Mr. Raghu Rao | Interim Chief Executive Officer & Director | 116,500 | 1963 |
| Mr. Donald J. Griffith CPA, CPA | Chief Financial Officer, Financial Controller & Director | 90,256 | 1949 |
| Dr. John K. Cini Ph.D. | Chief Scientific Officer & Co-Founder | 397,750 | 1953 |
| Mr. Manuel Dafonseca | Head of Clinical Operations | 0 | N/A |
| Dr. Stephen J. McAndrew Ph.D. | President & Chief Business Officer | 0 | 1954 |
| Dr. Richard T. Kenney FACP, M.D. | Chief Medical Officer | 0 | 1958 |
| Ms. Susan Dexter | Chief Technical Officer | 0 | 1955 |
| Dr. Gael Hedou Ph.D. | Chief Operating Officer | 0 | 1972 |
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.